Onkologie. 2015:9(3):112-118

Myelodysplastic syndrome

Libor Červinek
Interní hematologická a onkologická klinika LF MU a FN Brno

Myelodysplastic syndrome is a clonal haemopoietic disorder that is manifested with a peak at the age of 65 to 72 years. The pathophysiology

of the disease is associated with genetic changes in the stem cell‘s nucleus. In terms of diagnosis, it is essential to examine the bone

marrow and provide cytogenetic and, optionally, molecular genetic testing, on the basis of which the disease is classified accurately and

the patient‘s prognosis and optimal treatment are determined. The treatment strategy can be divided into two groups. The treatment

recommended for patients with low risk consists of supportive, stimulation, or immunomodulatory therapy. The treatment of high-risk

patients involves the administration of hypomethylating agents or chemotherapy with subsequent haemopoietic stem cell transplantation.

Keywords: myelodysplastic syndrome, IPSS, IPSS-R, lenalidomide, azacitidine

Published: June 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Červinek L. Myelodysplastic syndrome. Onkologie. 2015;9(3):112-118.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Malcovati L, Hellström-Lindberg E, Bowen D, Cermak J, Cazzola M; European Leukemia Net. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013; 122(17): 2943-2964. Go to original source... Go to PubMed...
    2. Sally B. Kilick, Chris Carter, Dominic Culligan at all Guidelines for the diagnosis and management of adult myelodysplastic syndromes British Journal of Haematology 2014 Br J Haematol. 2014: 1649.
    3. Schanz J, Tüchler H, Solé F, et al.New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 30: 820-829.
    4. van de Loosdrecht AA, Westers TM, Identification of distinct prognostic subgroupsin low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood. 2008; 111(3): 1067-1077. Go to original source... Go to PubMed...
    5. Bravo Montalbán Giulermo et al. Intregrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution British Journal of Haematology 2014; 166: 645-659. Go to original source... Go to PubMed...
    6. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes.et al. Blood. 2012; 120: abstract Go to original source...
    7. Jonasova A, Fuchs O, The response of FLi1, EKLF, TP53 (p53), PU.1, MDM2 gene expression in 5q- syndrome to lenalidomide treatment Leukemia Research 05/2011; 35. DOI: 10.1016/S0145-2126. Go to original source...
    8. Fuchs O, Polak J, The Efficacy of lenalidomide in lower risk myelodysplastic syndrome with isolated 5q deletion is dependent on high level of full-lenght cereblon messenger RNA Leukemia Research 04/2015; 39:S18-S19. DOI: 10.1016/S0145-2126(15)30043-6. Go to original source...
    9. Greenberg P, Cox C, LeBeau MM, et al. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079-2088. Go to original source...
    10. Greenberg P, Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood. 2012;120: 2454-65. Go to original source... Go to PubMed...
    11. Fenaux P, Ades L. Bl et all How we treat lower-risk myelodysplastic syndromes Blood; 121, 2013: 42080-4286. Go to original source... Go to PubMed...
    12. Gattermann N, Jarisch A, Schlag R, et al. Deferasirox treatment of iron-overloaded chelation-na?ve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange. Eur J Haematol. 2012; 88(3): 260-268. Go to original source... Go to PubMed...
    13. Cermak J, Jonasova A, Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome. Hemoglobin. 2011; 35(3): 217-227. Go to original source... Go to PubMed...
    14. Casu C, Rivela S Iron age: novel targets for iron overload Hematology 2014; American Society of Hematology Education program 216-221. Go to original source...
    15. Hellstrom-Lindberg E et al Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br JHaematol. 2003; 120(6): 1037-1046. Go to original source... Go to PubMed...
    16. List A et al. Efficacy of lenalidomide in myelodysplastic syndromes N Engl J Med. 2005; 352: 549-557. Go to original source... Go to PubMed...
    17. Ebert B, An erythroid differentiation signature predicts response tolenalidomide in myelodysplastic syndrome. PLoS Med. 2008; 5(2): e35. Go to original source... Go to PubMed...
    18. Fenaux P, Giagounidis A al; MDS-004 Lenalidomide del5q Study Group. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood.2011; 118(14): 3765-3776. Go to original source... Go to PubMed...
    19. Santini V at all Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del (5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005). ASH 2014 Poster 409.
    20. Jonasova A, Neuwirtová R, Cermak J Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. British Journal of Haematology Volume 100, Issue 2, pages 304-309, February 1998. Go to original source... Go to PubMed...
    21. Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented inmyelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2002; 100(5): 1570-1574. Go to original source...
    22. Fenaux P, Mufti G, Hellstrom.Lindberg E et all Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open label, phase III study Lancet Oncol 2009; 10: 223-232. Go to original source... Go to PubMed...
    23. Santini V, Fenaux P, Mufti G Management and supportive care measures for advers events in patinents with myelodysplastic syndromes treated with azacitidine Eur J Haematol 2010; 85: 130-138. Go to original source... Go to PubMed...
    24. Müller-Thomas C, Rudelius M at al Response To Azacitidine Is Independent Of TP53 Mutations In Higher-Risk Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML) Blood 2013; 122(21): 2797. Go to original source...
    25. Platzbecker U, Bornhauser M, Germing U, et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novomyelodysplastic syndrome (MDS). Blood Marrow Transplant. 2008; 14(11): 1217-1225. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.